Drugs / granulocyte colony-stimulating factor (G-CSF)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00003838 Background | Apr 1999 → Dec 2018 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | granulocyte colony-stimulating factor (G-CSF) | “granulocyte colony-stimulating factor (G-CSF)” NCT00003838 ↗ |
| Known as | G-CSF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003838 ↗ |
| Route | Subcutaneous | “G-CSF will be administered based on body weight for at least 5, and up to 7 days, subcutaneously.” NCT00003838 ↗ |